Clinical Trial

A Study of EDG-15400 in Healthy Adults

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purposes of this Phase 1 study of EDG-15400 are to: 1. Learn about the safety of EDG-15400 after single and multiple doses in healthy adults 2. Learn about how EDG-15400 is tolerated after single and multiples doses in healthy adults 3. Evaluate the amount of EDG-15400 in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-15400 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-15400 in the blood is similar for the suspension and tablet forms of EDG-15400 in healthy adults Participants will receive a single or multiple doses of EDG-15400 or a placebo by mouth.
Protocol Amendment History 2 changes
critical Trial completed 2026-08-06
notable Enrollment reduced: 108 -> 84 participants 2026-08-06
Trial Details
NCT Number NCT07177066
Lead Sponsor Edgewise Therapeutics, Inc.
Conditions Healthy Adults
Enrollment 84 participants
Start Date 2025-08-20
Primary Completion 2026-04-29 (estimated)
Study Completion 2026-04-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-05